Articles Accepted

The current research work aimed at improving solubility of dolutegravir sodium (BCS class II) utilizing the approach of co-crystallization and formulating orodispersible tablet of chosen co-crystals to maximize the therapeutic use of Dolutegravir sodium. Co-crystals have been prepared by solvent evaporation method. Thus prepared co-crystals have been subjected for Solubility analysis, Melting point determination, FTIR, DSC and PXRD analysis. Co-crystals prepared using various co-formers have shown increment in solubility. Dolutegravir sodium - Maltitol co-crystals have demonstrated four times higher solubility than primary drug which is profound among all the co-crystals. The FTIR study revealed changes in featured spikes of Dolutegravir sodium co-crystals compared to pure drug. DSC results indicated an additional endothermic peak as well as modification typical exothermic peak in the thermogram of Dolutegavir sodium co-crystals. The pattern of x-ray diffractogram of dolutegravir sodium co-crystals showed variations in degrees of high peaks. Therefore, co-crystal synthesis has been confirmed. All the parameters of orodispersible tablet were found to be within the acceptable range. The optimized formulation of co-crystal has shown profound drug release compared with the pure drug formulation. The formulations were stable for period of one month.